Zelasudil
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 13, 2021 (NCT04931147)
Timeline
Indications
Mechanism of action
- Rho-associated protein kinase 2INHIBITOR
ROCK2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1nc(-c2ccc(C(=O)NCC(F)F)cc2)nc1Nc1ccc2[nH]ncc2c1C1CC1- Mol. weight
- 437.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314495 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05570058 | Phase 2 | Sep 8, 2022 | Imperial College London, Redx Pharma Plc, Simbec-Orion, University of Southern California |
| NCT04931147 | Phase 1 | May 13, 2021 | Redx Pharma Plc, Simbec-Orion |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Redx Pharma Plc | For profit | 2 | 2 | 2 | 2021 |
| Simbec-Orion | For profit | 2 | 0 | 2 | 2021 |
| Imperial College London | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Southern California | Academic/Hospital | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1